What's the recommended schedule for lurbinectedin side effect checks?

Recommended Monitoring Schedule for Lurbinectedin Side Effects

Lurbinectedin (Zepzelca) requires frequent monitoring due to risks like myelosuppression, hepatotoxicity, and rhabdomyolysis. The FDA label outlines checks tied to dosing every 21 days.[1]

Blood Counts (Myelosuppression)

• Complete blood count (CBC) with differential before each cycle.
  
• Weekly CBC for the first two cycles, then before subsequent cycles if grade 3/4 neutropenia or grade 4 thrombocytopenia occurs.
  
• Delay dosing until neutrophils recover to ≥1.5 × 10^9/L and platelets to ≥100 × 10^9/L.
  
  

Liver Function Tests (Hepatotoxicity)

• Monitor ALT, AST, and bilirubin before each cycle.
  
• More frequent testing if transaminase elevation occurs; hold or discontinue for grade 3/4 increases.
  
  

Creatine Phosphokinase (CPK) Levels (Rhabdomyolysis Risk)

• Baseline CPK before treatment.
  
• Monitor periodically, especially with symptoms like muscle pain or weakness; discontinue if CPK >5× upper limit of normal with renal injury.
  
  

Other Checks

• Assess for hyperglycemia and tumor lysis syndrome before each cycle, particularly in high-risk patients.
  
• Vital signs and physical exam per standard oncology practice, with ECG if QT prolongation suspected.
  
  Guidelines from NCCN align with these, emphasizing individualized adjustments based on toxicity grade.[2]
  
  [1] FDA Label for Zepzelca (lurbinectedin)
  [2] NCCN Guidelines for Small Cell Lung Cancer, Version 1.2024